DWP 09031

Drug Profile

DWP 09031

Alternative Names: DWJ-302; DWP09031

Latest Information Update: 04 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 04 Apr 2016 Phase I development is ongoing in South Korea
  • 25 Apr 2014 DWP 09031 is available for licensing (http://www.daewoong.com/)
  • 06 Mar 2012 Daewoong Pharmaceutical receives grant from Korean Pan-Ministry and Full Cycle New Drug Development Group for DWP 09031 development in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top